Whether it's a new injury or an old one, it's never too late to start this peptide therapy with Iowa IV
Endothelial cell tube formation, a laboratory measure of angiogenic potential, shows a statistically significant increase in BPC-157-treated cultures compared to untreated controls in published in vitro research
Important Information This program is provided under medical supervision only
7 Science-Backed Benefits of BPC-157 Peptide 1
(2000), Horm Res 53(Suppl 3), PubMed 10971106 Statistics from preclinical literature AOD-9604 = modified fragment of hGH 177191 + N-terminal Tyr (sequence Tyr-Leu-Arg-Ile-Val-Gln-Cys-Arg-Ser-Val-Glu-Gly-Ser-Cys-Gly-Phe), molecular weight 1815.1 Da Developed at Metabolic Pharmaceuticals (Australia) based on the work of professor Frank Ng (Monash University) in the 1990s Standard experimental dose in obesity clinical trials: 1 mg/day subcutaneously (Phase 2b, Heffernan et al.) Mechanism: stimulation of 3-adrenergic receptors in adipose tissue, increased lipolysis and fatty acid oxidation without activation of the hGH receptor (no IGF-1 increase) Phase 2b clinical trial (2007, 300 patients): weight reduction ~2.8 kg vs placebo over 12 weeks FDA status: NDI rejection (2014) as a dietary supplement
Targeted adipose & lipid metabolism: AOD-9604 is frequently investigated for its role in lipolysis signaling and adipocyte-related pathways, supporting research into fat metabolism and body-composition endpoints
